Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial

Overview of attention for article published in Nature Medicine, October 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)

Mentioned by

news: 1 news outlet

twitter: 1 X user

So far, Altmetric has seen 1 news story.

Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.

Alzforum, 07 Oct 2022

Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.